• Patricia Gómez-Rosas, Miguel Á Sosa-Velázquez, Lesly A Yáñez-Funes, José J González-Trejo, Karim Majluf-Cruz, Irma Isordia-Salas, Gregorio Ignacio-Ibarra, Martín Almaraz-Delgado, Luis A Moreno-Ruiz, Jesús S Valencia-Chávez, Jesús Hernández-Juárez, David Vázquez-Rubiel, Víctor Domínguez-Reyes, Rodrigo Arreola-Díaz, Ma Teresa García-Lee, Jorge Vela-Ojeda, and Abraham Majluf-Cruz.
• Thrombosis, Hemostasis and Atherogenesis Medical Research Unit. Instituto Mexicano del Seguro Social, Mexico City. Mexico.
• Gac Med Mex. 2021 Jan 1; 157 (3): 284-292.

IntroductionVitamin K antagonists (VKA) are a therapeutic alternative in patients with venous thromboembolic disease; however, numerous factors affect their pharmacology.ObjectiveTo evaluate the quality of VKA anticoagulation at three different time periods in Mexico.MethodsProspective study, nested in patient cohorts at three different clinical scenarios between 2013 and 2019. Outpatients with indication for treatment with VKAs for at least 12 months were included. Patients were managed according to the criteria of the treating physician.ResultsPatient general characteristics were similar between groups, except for the VKA indication. The results of 4,148 patients and 38,548 INR assessments were analyzed. The times in therapeutic range during the three phases of the study and pooled data were significantly higher for the anticoagulation clinic. Only the number of patient visits was significantly associated with the results, unlike age, gender, and type of VKA.ConclusionsVKAs are widely used, but it is difficult for therapeutic goals to be achieved, especially in non-specialized clinical services. Creation of anticoagulation clinics is an urgent need for the Mexican health system.Copyright: © 2021 Permanyer.

15 keywords...

hide…